ArticleActa dermato-venereologica2026
The Use of Systemic Immunomodulating Drugs and Management Practices in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis among Dermatologists in the Philippines: A Cross-sectional Survey Study.
Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, life-threatening cutaneous adverse drug reactions with potential morbidity and mortality. Despite increasing use of systemic immunomodulatory therapies, consensus regarding optimal medical management remains lacking, particularly in resource-limited settings. We evaluated management practices and treatment preferences for SJS/TEN among board-certified dermatologists in the Philippines using a clinical vignette-based (CV) survey approach.
methodsA cross-sectional online survey was conducted among Philippine board-certified dermatologists from January to June 2025. The survey assessed res-pondent characteristics, clinical experience with SJS/TEN, management practices, referral patterns, and treatment preferences across six6 standardized CVs. Ordinal data were analysed using weighted scores, Friedman tests, and Kendall's coefficient of concordance to assess inter-physician agreement..
resultsThere were forty-eight48 dermatologists participated. Most respondents reported prior SJS/TEN experience and inpatient clinical exposure. Corticosteroids were the most commonly used systemic therapy (85.4%), while 35.4 % reported managing selected cases with supportive care alone. Significant differences in treatment rankings were observed across all six6 vignettes (all p<0.001). Agreement was large for CV1 (W=0.516), moderate for CV2-5 (W=0.398-0.465), and small for CV6 (W=0.236). Corticosteroids and IVIG consistently ranked highest, while other immunosuppressants showed scenario-dependent variability.
conclusionsThe use of systemic immunosuppressants remains to be preferred in SJS/TEN treatment. However, treatment practices among Filipino dermatologists demonstrate substantial heterogeneity especially in complex cases. These findings highlight the need for stratified treatment frameworks and persistent uncertainty in SJS/TEN management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.